Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/2229-516X.157177 http://scihub22266oqcxt.onion/10.4103/2229-516X.157177 C4456896!4456896!26097830     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Appl+Basic+Med+Res 2015 ; 5 (2): 157-8 Nephropedia Template TP {{tp|p=26097830|t=2015. Phentermine-topiramate: First combination drug for obesity |pdf=|usr=}}{{26097830}} gab.com Text Phentermine-topiramate: First combination drug for obesity JO: Int J Appl Basic Med Res http://www.kidney.de/pget.php?&tw=1&pmid=26097830 #FOAvip Obesity is spreading globally at an alarming speed. The management of obesity is multifaceted and includes lifestyle modifications as the cornerstone. Until only orlistat was approved for long term use in obesity. The US Food and Drug Administration granted approval to a fixed dose mid 2012 combination of phentermine immediate release and topiramate extended release in 2012 for treatment of obese patients or overweight patients with comorbid conditions. The new drug has shown significant weight loss compared with placebo for a period up to 2 years. Twit Text FOAVip Phentermine-topiramate: First combination drug for obesity ????Int J Appl Basic Med Res http://www.kidney.de/pget.php?&tw=1&pmid=26097830 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26097830 #FOAvip English Wikipedia <ref>{{Cite pmid|26097830}}</ref> Phentermine-topiramate: First combination drug for obesity #MMPMID26097830 Singh J; Kumar R Int J Appl Basic Med Res 2015[May]; 5 (2): 157-8 PMID26097830show ga Obesity is spreading globally at an alarming speed. The management of obesity is multifaceted and includes lifestyle modifications as the cornerstone. Until only orlistat was approved for long term use in obesity. The US Food and Drug Administration granted approval to a fixed dose mid 2012 combination of phentermine immediate release and topiramate extended release in 2012 for treatment of obese patients or overweight patients with comorbid conditions. The new drug has shown significant weight loss compared with placebo for a period up to 2 years. äPhentermine-topiramate: First combination drug for obesity (epmc).pdf DeepDyve Pubget Overpricing